Literature DB >> 3097131

Regulation of human T lymphocyte mitogenesis by antibodies to CD3.

L Davis, R Vida, P E Lipsky.   

Abstract

The inhibitory and mitogenic effects of anti-CD3 antibodies (anti-CD3) were examined in cultures of human peripheral blood T cells. Resting T cells required the presence of accessory cells (AC) or phorbol myristate acetate (PMA) to be stimulated by soluble anti-CD3 (OKT3 and 64.1). Anti-CD3 was unable to induce activation of AC-depleted T cells as determined by IL 2 receptor expression, IL 2 production, cell cycle analysis, or detectable DNA synthesis. Although T cell responses to PHA also required AC, far fewer were necessary to generate responses. Anti-CD3 inhibited PHA-stimulated T cell IL 2 production, IL 2 receptor expression and proliferation in partially AC-depleted cultures. Moreover, anti-CD3 was able to inhibit PHA responses when added to culture as late as 24 to 42 hr after the initiation of a 96-hr incubation. Increasing concentrations of PHA reduced the inhibitory effect of anti-CD3 on PHA-stimulated T cell proliferation, whereas IL 2 production remained suppressed. Anti-CD3 linked to Sepharose beads effectively inhibited PHA-stimulated T cell DNA synthesis, indicating that internalization of the CD3 molecule was not required for inhibition of PHA responses. Although inhibition of IL 2 production was a major effect of anti-CD3 in PHA-stimulated cultures, it was not the only apparent inhibitory effect because the addition of exogenous IL 2 could not prevent inhibition completely. Intact AC but not IL 1 also reduced anti-CD3-mediated inhibition of PHA responsiveness, whereas the addition of both IL 2 and AC largely prevented inhibition. Thus, anti-CD3 in the absence of adequate AC signals exerted a number of distinct inhibitory effects on mitogen-induced T cell activation. These results suggest that the CD3 molecular complex may play a role in regulating T cell responsiveness after engagement of the T cell receptor by a number of mechanisms, some of which involve inhibition of IL 2 production.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3097131

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Peripheral T-lymphocyte activation by human T-cell leukemia virus type I interferes with the CD2 but not with the CD3/TCR pathway.

Authors:  M D Dodon; A Bernard; L Gazzolo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

2.  Interactions of CD4+ and CD8+ human T lymphocytes from malaria-unprimed donors with Plasmodium falciparum schizont stage.

Authors:  C Roussilhon; M Agrapart; C Behr; P Dubois; J J Ballet
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

3.  Diminished T lymphocyte proliferative response to polyclonal mitogens in acute brucellosis patients.

Authors:  M Rodriguez-Zapata; M Alvarez-Mon; I Salmeron; A Prieto; L Manzano; O J Salmeron; J Carballido
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

4.  Characterization of ionotropic glutamate receptors in human lymphocytes.

Authors:  G Lombardi; C Dianzani; G Miglio; P L Canonico; R Fantozzi
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

5.  Cytomegalovirus (CMV) infection in AIDS patients is associated with a CD3 receptor-mediated T cell hyporesponsiveness.

Authors:  A W Rowbottom; M W Lepper; D Sharpstone; B Gazzard
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

6.  Regulation of interleukin 3 gene induction in normal human T cells.

Authors:  S C Guba; G Stella; L A Turka; C H June; C B Thompson; S G Emerson
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.

Authors:  S C Helfand; S A Soergel; P S MacWilliams; J A Hank; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

8.  Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin-2 deficiency.

Authors:  M D Köller; H P Kiener; M Aringer; W B Graninger; S Meuer; Y Samstag; J S Smolen
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

9.  CCA [N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt], a newly developed immunomodulating drug, suppresses T-cell activation by acting on macrophages.

Authors:  T Takeuchi; J Koide; O Hosono; M Takano; T Abe
Journal:  Inflammation       Date:  1989-04       Impact factor: 4.092

10.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.